Delving into the Latest Updates on Allife Medicine (Zhuhai Hengqin New Area) Co., Ltd. with Synapse

Overview

Tags

Urogenital Diseases

Neoplasms

Endocrinology and Metabolic Disease

Stem cell therapy

Fusion protein

Antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	2
Neoplasms	2
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Stem cell therapy	4
Antibody	1
Induced pluripotent stem cells (iPSC)	1
Fusion protein	1

Top 5 Target	Count

FLNB(filamin B)	1
CD8A x Immunoglobulin like domain containing	1
PSMA(Prostate-specific membrane antigen)	1

主要研究目的：评价EPCs治疗急性缺血性脑卒中患者的安全性和耐受性，以及为后续临床研究推荐剂量。次要研究目的： 1.评价EPCs治疗急性缺血性脑卒中患者的免疫原性； 2.评估EPCs治疗急性缺血性脑卒中患者的药物代谢动力学特征； 3.探索EPCs治疗急性缺血性脑卒中患者的剂量与临床疗效的效应关系； 4.观察EPCs治疗急性缺血性脑卒中患者的初步疗效。探索性研究目的：探索EPCs治疗急性缺血性脑卒中患者的药效学特征。

[Translation]

Main research objectives: To evaluate the safety and tolerability of EPCs in the treatment of patients with acute ischemic stroke, and to recommend doses for subsequent clinical studies. Secondary research objectives: 1. To evaluate the immunogenicity of EPCs in the treatment of patients with acute ischemic stroke; 2. To evaluate the pharmacokinetic characteristics of EPCs in the treatment of patients with acute ischemic stroke; 3. To explore the relationship between the dose and clinical efficacy of EPCs in the treatment of patients with acute ischemic stroke; 4. To observe the preliminary efficacy of EPCs in the treatment of patients with acute ischemic stroke. Exploratory research objectives: To explore the pharmacodynamic characteristics of EPCs in the treatment of patients with acute ischemic stroke.

Start Date-

Sponsor / Collaborator

Allife Medicine (Zhuhai Hengqin New Area) Co., Ltd.

100 Clinical Results associated with Allife Medicine (Zhuhai Hengqin New Area) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Allife Medicine (Zhuhai Hengqin New Area) Co., Ltd.

Login to view more data

100 Deals associated with Allife Medicine (Zhuhai Hengqin New Area) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Allife Medicine (Zhuhai Hengqin New Area) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

3

IND Application

Phase 1 Clinical

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AFL-101	Ovarian Epithelial Carcinoma More	Phase 1
Allogenic endothelial progenitor cells(Allife Medicine)	Acute Ischemic Stroke More	Phase 1
ALF401	dry age-related macular degeneration More	IND Application
ALF50X ( PSMA )	Prostatic Cancer More	IND Application
ALF301	Diabetes Mellitus, Type 2 More	IND Application